The BRIT report 2025: A summary of data held by the BSACI Registry for Immunotherapy (BRIT)
No Thumbnail Available
Authors
ErlewynLajeunesse M.
Michaelis L.
Villa L.P.
Achunche S.
Maslovskaya O.
Smith M.
Baigel R.
Dawson T.
Gourgey R.
Kelly M.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Objectives: BRIT is the national registry for allergen immunotherapy and high tariff drugs. It was launched at the BSACI Conference in 2018. BRIT records treatment domains: Aeroallergen (AIT), Venom (VIT) and Peanut Immunotherapy (PIT) and Omalizumab for Chronic Spontaneous Urticaria (MAB). Method(s): BRIT is a secure web-based registry accessible to UK-based BSACI Consultant members, enabling clinicians to enter participant data from hospital or office settings. Patient participants give written consent to join the registry and return patient related outcome measures (PROM) directly by response to automated SMS/email or by manual entry by clinicians. The data were downloaded on 15th January 2025. Result(s): 3,532 participants were recruited by 99 lead practitioners across 74 sites. 45.6% (1611) were children under 16 years old.19.2% (679) were of Black, Asian or Minority Ethnic (BAME) background. 94.0% (3319) were NHS patients. 54.8% (1935) were male. 93.4% (3300) lived in England, with 1019 (28.9%) from Greater London, and 178 (5.0%) from the Devolved Nations. Treatment domains included AIT 2,382, 67.4%, VIT 657, 18.6% MAB 375, 10.6%, PIT 103, 2.9%, unknown 15, 0.4%. 8,284 PROM were returned directly by participants or manually input by practitioners. There were 263 adverse events reported, 59 (22%) leading to discontinuation of treatment. Conclusion(s): BRIT demonstrates successful nationwide engagement in allergen immunotherapy and high-cost drug monitoring with strong representation across age, ethnicity, and treatment domains. Although the registry is London centric there is increasing engagement from other parts of the UK. High participant numbers, PROM returns, and adverse event reporting highlight the registry's value in supporting real-world data collection to inform clinical practice and improve patient outcomes in allergy care.
Description
Citation
Publisher
License
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology